Abbvie (ABBV) Revenue (2012 - 2026)
Abbvie (ABBV) revenue from Mar 31, 2012 to Mar 31, 2026. The TTM Abbvie (ABBV) revenue is $63B. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual Revenue
Quarterly Revenue
Abbvie (ABBV) Revenue CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | +9.50% |
| 3 Years TTM | +3.45% |
| 5 Years TTM | +4.59% |
| 10 Years TTM | +10.20% |
| All Time TTM | +9.84% |
Annual Revenue change of Abbvie (ABBV)
| Year | Revenue | Change |
|---|---|---|
| 2026 | $15B | -75.47% |
| 2025 | $61B | +8.57% |
| 2024 | $56B | +3.71% |
| 2023 | $54B | -6.44% |
| 2022 | $58B | +3.30% |
| 2021 | $56B | +22.69% |
| 2020 | $46B | +37.69% |
| 2019 | $33B | +1.57% |
| 2018 | $33B | +16.08% |
| 2017 | $28B | +10.06% |
| 2016 | $26B | +12.16% |
| 2015 | $23B | +14.52% |
| 2014 | $20B | +6.23% |
| 2013 | $19B | +2.23% |
| 2012 | $18B | +5.37% |
| 2011 | $17B | N/A |
Comparison Abbvie (ABBV) five years revenue CAGR with competitors
Abbvie (ABBV) five years revenue CAGR is 4.59%.
| Ticker | Name | five years Revenue CAGR | Upside |
|---|---|---|---|
| LLY | Lilly(Eli) & Company | 23.17% | +404.92% |
| NVO | Novo Nordisk | 20.75% | +352.12% |
| AZN | Astrazeneca plc | 16.99% | +270.15% |
| MRK | Merck & Co Inc | 10.41% | +126.80% |
| AMGN | AMGEN Inc | 8.14% | +77.45% |
| PFE | Pfizer Inc | 6.56% | +42.93% |
| GRFS | Grifols SA | 5.39% | +17.54% |
| SNY | Sanofi | 5.03% | +9.56% |
| GILD | Gilead Sciences Inc | 3.07% | -33.11% |
| JNJ | Johnson & Johnson | 2.73% | -40.47% |
| BMY | Bristol-Myers Squibb Company | 2.52% | -45.09% |
| NVS | Novartis AG | 2.36% | -48.59% |
| GSK | GSK Plc | 0.63% | -86.22% |